You are here: Industry Insights > Chime Biologics

News List

Humanigen Selects Chime Biologics as Manufacturing Partner contractpharma
May 18, 2021
Humanigen, a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, and Chime Biologics, a contract development and manufacturing ...
Chime Biologics Expands CDMO Capabilities contractpharma
March 30, 2021
Chime Biologics, a China-based CDMO, has secured a total commitment of $190 million investment from institutional investors.
Chime Biologics Announced the Completion of US$190 Million Series A+ Financing to Accelerate Capacity Expansion prnasia
March 26, 2021
Chime Biologics, a China-based, world-class CDMO company, announced today that it has secured a total commitment of US$190 million investment from institutional investors, and over $100 million investment has already been closed today.
Chime Biologics announces Marc Funk as new Board Director prnasia
March 22, 2021
Chime Biologics is pleased to announce the appointment of Marc Funk to its Board of Directors. Marc brings more than 20 years of leadership and industry experience in the global CDMO space.
Chime Biologics Supports COVID-19 Outbreak in Wuhan contractpharma
March 13, 2020
Chime Biologics, a China-based contract development and manufacturing organization (CDMO) providing fully-integrated services to support development and manufacturing of complex biologic ...